POD24: progression of follicular lymphoma within two years, and why it changes the plan

The National LymphoCare Study followed 588 patients with stage 2 to 4 follicular lymphoma given first-line R-CHOP. Progression within two years of diagnosis happened in 19 per cent, and five-year overall survival in that group was 50 per cent against 90 per cent in everyone else; the effect held after adjusting for FLIPI (hazard ratio 6.44) and reproduced in an independent set of 147 patients. POD24 has since been shown with other induction regimens and is now the standard way of dividing follicular lymphoma into the part that behaves indolently and the part that does not.

What it changes. First, it triggers a repeat biopsy, because transformation to diffuse large B-cell lymphoma is the commonest reason for early progression and is treated as aggressive lymphoma, not as follicular lymphoma. Second, it moves the patient up the queue for treatment that works independently of chemotherapy sensitivity: CAR-T (axicabtagene ciloleucel or tisagenlecleucel) and the CD20 bispecific antibodies (mosunetuzumab, odronextamab, epcoritamab with rituximab and lenalidomide) all enrolled POD24 patients in numbers and reported response rates in them close to the whole-trial rates. Third, it is a reason to consider a clinical trial rather than a second line of chemoimmunotherapy.

POD24 is a description, not a diagnosis. It does not change the disease under the microscope, and a person who progresses at 25 months is not meaningfully different from one who progresses at 23.